Search Results

Nykode Therapeutics ASA announced that it has entered into a strategic manufacturing partnership with Richter-Helm BioLogics GmbH & Co KG to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio.

TransPerfect Life Sciences, a leading global provider of solutions for product development and launch for the biopharmaceutical industry, announced that Gedeon Richter selected Trial Interactive’s award-winning eTMF platform and TI Collaborate eClinical solution for its upcoming clinical trials.

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related indications.

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Gedeon Richter Plc. (‘Richter’) together with Sumitomo Pharma America, Inc. (‘SMPA’) and Sumitomo Pharma Switzerland GmbH (‘SMPS’) today announce that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO®.

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while responding positively to the announcement that Julie Kim will take the helm of the Japanese giant in 2026.

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a BioSpace analysis. This is happening in an era of biotech where new company founders are searching for CEOs with a track record.

IO Biotech announced that biopharma executive Christine Richter joined the company as SVP, Commercial and Program Lead for IO102-IO103, the company’s lead cancer vaccine candidate.